| Our Lab
Our lab is equipped with a collection of state of the art instruments to enable miniaturization and automation of a variety of biological assays. The automated system is comprised of:
High Content Screening (HCS) Platform, which is an automated cellular imaging and analysis platform designed for quantitative microscopy.
● Flow Cytometry, which enables multi-parametric single cell analysis.
● Automated workstation, for liquid handling for dispensing accurate and reproducible volumes of liquids and compounds.
● Multimode microplate reader designed for fast measurements of numerous biological reactions/processes.
Readouts generated from these instruments provide us with insights to the effect of our cannabinoid library on parameters such as, proliferation inhibition, apoptosis induction, angiogenesis and toxicity on cancerous cells.
| High Throughput Screening
The HTS platform allows us to test many compounds on cancerous cell lines and tissues and measure the therapeutics effects of these compounds.
Our advantage is in the specialized library which is composed of a collection of cannabis extracts and pure natural and synthetic cannabinoids. The library will also include a costumed cannabinoid matrix, to assess the possible interaction of combination therapy.
These experiments will produce multiplexed data composed of images of cells, cell specific markers and the extent/signal of the biological response. The biological response will be measured using different concentration of cannabinoids and their combinations, thus determining the most effective cannabinoid treatment for a specific cancer type.
| Predictive Analytics
Data analytics are a key component of the novel platform developed by Cannabics in its efforts to enable practitioners to precisely tailor medical cannabinoid-based therapies to an individual patient’s profile and cancer. We are developing a proprietary platform employing cutting-edge machine learning algorithms and deep learning models. Our data technology integrates large quantities of multi-omic profiles, environment and lifestyle data into a high content drug sensitivity screening pipeline, enabling the development of highly personalized models that practitioners can rely on as preventative, primary and complementary cannabinoid-based treatment options.
| Cannabics SR
We developed a proprietary capsule shown to provide patients with long lasting effects of 10-12 hours.
While the medicinal effects of certain cannabinoids are well known to physicians, it is common knowledge that smoking is hazardous to health. Many physicians are perfectly aware of the palliative properties of cannabis (i.e anti-emetic and analgesic), however they refrain from recommending or prescribing it to patients knowing that smoking the raw flowers remains the most common.
| Clinical Trials
While many anecdotal reports by cancer patients using various formulations of Cannabinoids suggest significant efficacy, the lack of pure pharmacologically active compounds and legal restrictions have delayed the clinical research; that will ultimately determine the level at which cannabinoids are effective in the treatment of cancer beyond their proven palliative effects. Thus, only a few clinical trials have been conducted aiming to confirm the antineoplastic activity of cannabinoids.
Cannabics has successfully conceptualized, funded, executed and concluded two clinical trials, Cannabics SR 5mg for Cancer Anorexia Cachexia Syndrome – CACS, and for the Screening of Potential Anticancer Cannabinoid Compounds.
The main purpose in the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS) is to prolong life and to improve the quality of life (QoL) as far as possible. QoL in patients with CACS is directly related to loss of appetite and loss of weight. Cannabis pills are given in Israel to advanced cancer patients with various symptoms in order to improve their QoL. There is data on safety/toxicity of cannabis, and these pills are given under the regulations of the Israel Ministry of Health.
The purpose of this study is to examine the influence of Cannabics capsules on improving loss of appetite and loss of weight.
More information here
Our policy is to seek patent protection for the technology, inventions and improvements that we consider important to the development of our business, but only in those cases where we believe that the costs of obtaining patent protection is justified by the scientific and commercial potential of the technology, and typically only in those jurisdictions that we believe present significant commercial opportunities. We anticipate that we will file
additional patent applications in conjunction with our research, testing, and development of our cannabis-based products.